NFE2L2 and lung carcinoma: Additionally, the missense mutation rate of NFE2L2-D13N is 1.73% (13/751) in tumor patients, including 3.3% (9/272) in lung cancer, 2.02% (2/99) in liver cancer, and 1.01% (1/99) in esophageal carcinoma.